CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?

by Elisa Agostinetto
Published 2020-12-01

The Exciting New Field of HER2-Low Breast Cancer Treatment

by Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde, Evandro de Azambuja
Published 2021-03-01

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

by Elisa Agostinetto, Mattia Rediti, Danai Fimereli, Véronique Debien, Martine Piccart, Philippe Aftimos, Christos Sotiriou, Evandro de Azambuja
Published 2021-06-01

Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models

by Alessio Gerussi, Ambra Natalini, Fabrizio Antonangeli, Clara Mancuso, Elisa Agostinetto, Donatella Barisani, Francesca Di Rosa, Raul Andrade, Pietro Invernizzi
Published 2021-04-01

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

by Rita De Sanctis, Laura Giordano, Federica D’Antonio, Elisa Agostinetto, Arianna Marinello, Daniela Guiducci, Giovanna Masci, Agnese Losurdo, Monica Zuradelli, Rosalba Torrisi, Armando Santoro
Published 2021-06-01

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

by Rafael Caparica, Marco Bruzzone, Elisa Agostinetto, Maria Alice Franzoi, Marcello Ceppi, Nina Radosevic-Robin, Frédérique Penault-Llorca, Karen Willard-Gallo, Sherene Loi, Roberto Salgado, Evandro de Azambuja
Published 2021-10-01

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Itali...

by Raffaella Palumbo, Rosalba Torrisi, Federico Sottotetti, Daniele Presti, Anna Rita Gambaro, Elena Collovà, Antonella Ferzi, Elisa Agostinetto, Cristina Maria Teragni, Giuseppe Saltalamacchia, Barbara Tagliaferri, Emanuela Balletti, Antonio Bernardo, Erica Quaquarini
Published 2021-03-01